Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Susan Bernstein  |  Issue: June 2017  |  June 14, 2017

More competition and lower prices in this class of treatments is greatly needed, says Dr. Worthing.

“Specialty drugs, such as biologics, are only 1% of prescriptions in the U.S., but they constitute about a quarter of the U.S. drug spend. High drug prices in rheumatology are likely driving a lot of the administrative hassles and barriers to care, such as prior authorization and step therapy. This is why it’s critical to get biosimilars to market efficiently,” says Dr. Worthing.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a March 21, 2017, address to Congress, FDA Director Janet Woodcock, announced the hiring of additional staff to manage biosimilar approvals. Dr. Worthing says, “I am thrilled to see that the FDA can start hiring the experts needed to approve the backlog of 60+ biosimilars currently in the pipeline.”

Until biosimilars come down in price—if they do—other rheumatologists are skeptical about the benefit to arthritis patients already strapped with high costs for other medications and areas of care.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“I was a little disappointed when I saw the first pricing for the biosimilars. If you look at the costs, they are pretty comparable to the biologics, which was surprising,” says Piyush Poddar, MD, a rheumatologist with Sanford Health in Bismarck, N.D. “I have patients on Medicare who, if they don’t have supplemental, commercial policies too, they can’t afford biologics. Their monthly copay may be $1,000–2,000 a month. Some of my patients say they try to stretch the doses. They split their dose of some drugs. The drugs lose their efficacy.”

Not-So-Cheap Generics

Pricey biologics are not the only source of rising costs that concern rheumatologists. Generic drugs for rheumatologic conditions are going up in price, too.

“The costs that concern me the most are the high cost for a number of common generic medications, such as colchicine for gout and metalazone (Skelaxin), a non-sedating muscle relaxer,” says Scott Zashin, MD, a rheumatologist in private practive in Dallas. “These medications carry inexplicably high costs and can be a barrier to effective treatment.”

At his Omaha clinic, Dr. O’Dell is concerned by the rising costs of generic colchicine and hydroxychloroquine (Plaquenil). According to GoodRx.com, the average retail price of 60 tablets of 200 mg hydroxychloroquine is $220.05.

“Hydroxychloroquine has been used for 60 years at least. It used to be pennies a pill, and now it’s dollars a pill,” says Dr. O’Dell. He believes rising prices for generics are due to market forces, not research or development costs. “Hydroxychloroquine is a necessary medication for every patient with lupus. They should be on it and be taking it forever. Yet my lupus patients come in and say, ‘Doc, I’m not taking my hydroxychloroquine,’ or maybe, ‘I am taking a half dose, because I can’t afford it.’ That’s tragic.”

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Practice Support Tagged with:BiologicsBiosimilarsCompliancecostsdruggenericHealthcareMedicationpatient careRheumatic DiseaserheumatologistTreatment

Related Articles

    Generic-Drug Price Fixing: Is It Happening?

    May 17, 2018

    It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences